IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?
The possibility of extrapolation of indications for biosimilars is one of the issues widely discussed in modern literature. Currently, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) have identified specific conditions under which for biosimilars extrapolation of indic...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2016-06-01
|
| Series: | Issledovaniâ i Praktika v Medicine |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/137 |